Email updates

Keep up to date with the latest news and content from BMC Public Health and BioMed Central.

Open Access Research article

Incidence and survival in non-hereditary amyloidosis in Sweden

Kari Hemminki12*, Xinjun Li2, Asta Försti12, Jan Sundquist23 and Kristina Sundquist2

Author affiliations

1 Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany

2 Center for Primary Health Care Research, Lund University, Malmö, Sweden

3 Stanford Prevention Research Center, Stanford University School of Medicine, California, USA

For all author emails, please log on.

Citation and License

BMC Public Health 2012, 12:974  doi:10.1186/1471-2458-12-974

Published: 13 November 2012

Abstract

Background

Amyloidosis is a heterogeneous disease caused by deposition of amyloid fibrils in organs and thereby interfering with physiological functions. Hardly any incidence data are available and most survival data are limited to specialist clinics.

Methods

Amyloidosis patients were identified from the Swedish Hospital Discharge and Outpatients Registers from years 2001 through 2008.

Results

The incidence of non-hereditary amyloidosis in 949 patients was 8.29 per million person-years and the diagnostic age with the highest incidence was over 65 years. Secondary systemic amyloidosis showed an incidence of 1 per million and a female excess and the largest number of subsequent rheumatoid arthritis deaths; the median survival was 4 years. However, as rheumatoid arthritis deaths also occurred in other diagnostic subtypes, the incidence of secondary systemic amyloidosis was likely to be about 2.0 per million. The median survival of patients with organ-limited amyloidosis was 6 years. Most myeloma deaths occurred in patients diagnosed with unspecified or ‘other’ amyloidosis. These subtypes probably accounted for most of immunoglobulin light chain (AL) amyloidosis cases; the median survival time was 3 years.

Conclusions

The present diagnostic categorization cannot single out AL amyloidosis in the Swedish discharge data but, by extrapolation from myeloma cases, an incidence of 3.2 per million could be ascribed to AL amyloidosis. Similarly, based on rheumatoid arthritis death rates, an incidence of 2.0 could be ascribed to secondary systemic amyloidosis.